Rifampicin-Amlodipine Interaction: A Case Report of Hypertension Exacerbation

  • Sinchana Bojamma P.K Bapuji Pharmacy College, Davangere, Karnataka, INDIA
  • Narne Akhil Indian Institute of Public Health, Public Health Foundation of India, Hyderabad, Telangana, India.
Keywords: Antihypertensive, Antitubercular, Accelerated hypertension, CYP induction

Abstract

Introduction: Rifampicin, a first-line anti-tubercular therapy drug, is a strong inducer of hepatic cytochrome P450 (CYP). Amlodipine and metoprolol, two anti-hypertensives that are CYP substrates, have the potential to interact pharmacologically with rifampicin. Therefore, individuals with hypertension receiving rifampicin-based anti-tubercular therapy are at risk for worsening hypertension.

Case Details: We report a case of a 63-year-old female patient, who developed accelerated hypertension after initiating rifampicin. Later, up to four antihypertensive drugs were administered as part of a gradual increase in dosage but did not successfully lower blood pressure to a desirable level. After clinical pharmacist intervention, Tab. Amlodipine+Metoprolol 5 mg+50 mg was discontinued and the blood pressure measurements gradually improved.

Conclusion: We postulate that rifampicin diminished the therapeutic effect of amlodipine and metoprolol and hence recommend that prudent monitoring for worsening hypertension should be carried out in hypertensive patients with chronic kidney disease receiving anti-tubercular therapy.

Downloads

Download data is not yet available.

Author Biography

Sinchana Bojamma P.K, Bapuji Pharmacy College, Davangere, Karnataka, INDIA

Department of Pharmacy Practice

References

Alemu, A., Bitew, Z. W., Diriba, G., Seid, G., Eshetu, K., Chekol, M. T & Gumi, B. (2022). Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis. International Journal of Infectious Diseases.

Agrawal, A., Agarwal, S. K., Kaleekal, T., & Gupta, Y. K. (2016). Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. Indian Journal of Nephrology, 26(5), 322.

Cordeanu, E. M., Gaertner, S., Faller, A., Mirea, C., Lessinger, J. M., Kemmel, V., & Stephan, D. (2017). Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension. Fundamental & Clinical Pharmacology, 31(5), 587-589.

Duggal, R. K., & Agrawal, G. P. (2019). Interaction of rifampicin with antihypertensive medications in chronic kidney disease patients: Clinical implications. Indian Journal of Medical Specialities, 10(3), 174.

Lee, S. L., Lim, W. J., & Chai, S. T. (2020). Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?. Med J Malaysia, 75(5), 591.

Syed-Ahmed, M., & Narayanan, M. (2019). Immune dysfunction and risk of infection in chronic kidney disease. Advances in chronic kidney disease, 26(1), 8-15.

Published
2023-03-01
How to Cite
1.
Sinchana Bojamma P.K, Akhil N. Rifampicin-Amlodipine Interaction: A Case Report of Hypertension Exacerbation . jpadr [Internet]. 2023Mar.1 [cited 2024Jul.23];4(1):29-1. Available from: http://jpadr.com/index.php/jpadr/article/view/121